The new Sub-Group analysis of RE-L included 3623 patients with atrial fibrillation who had had a stroke or TIA before enrollment in the study. The results of the subgroup analysis were consistent with the overall trial results for the major efficacy and safety results. This was accomplished by an interaction analysis that the results have been found in patients with previous stroke or TIA in accordance with the overall result in the RE – L trial.3, showed confirmed..
With well controlled warfarin, dabigatran etexilate was comparative in the study: 2.3 – Substantial reduction in risk of stroke and systemic embolism – including haemorrhagic strokes with dabigatran 150 mg twice daily Significantly lower major Significantly lower major bleeding with dabigatran etexilate 110 mg – significantly lower life threatening and intracranial bleeding with both doses – significant reduction in vascular mortality with dabigatran 150 mg twice daily.By the end of which two years we have a best electronic thermal device ready, have to hope are tested in a big -scale clinical trial. – Unfortunately, usual today testing have is not always into obtain a final diagnosis to the run or representation symptoms of a patient What is is needed is Reset sensory testing techniques for pains better understand of the underlying mechanism of esophageal.